KTTA Pasithea Therapeutics Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1841330 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-84.0%
TTM EPS YoY68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-88.8%
ROA-82.6%
ROIC (approx.)-414.6%
Asset turnover—
Leverage & solvency
Liabilities / assets5.9%
Debt / equity0.00x
Current ratio15.67x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $4.46M | $3.69M | $2.94M | $2.74M | $1.36M | $2.15M | $1.73M | $1.51M |
| SG&A expense | $2.51M | $2.03M | $1.93M | $7.51M | $1.75M | $1.66M | $1.95M | $1.75M |
| Operating income | -$6.97M | -$5.71M | -$4.88M | -$10.26M | -$3.11M | -$3.81M | -$3.68M | -$3.26M |
| Pretax income | -$6.58M | -$5.27M | -$2.87M | -$10.11M | -$3.04M | -$3.72M | -$3.56M | -$3.18M |
| Net income | -$6.58M | -$5.27M | -$2.87M | -$10.11M | -$3.04M | -$3.72M | -$3.56M | -$3.18M |
| EBITDA | — | — | — | -$10.26M | -$3.09M | -$3.81M | -$3.68M | -$3.25M |
| EPS (basic) | -0.20 | -0.16 | -0.12 | — | -0.41 | -0.66 | -1.61 | — |
| EPS (diluted) | -0.20 | -0.16 | -0.12 | — | -0.41 | -0.66 | -1.61 | — |
| Weighted avg. shares (diluted) | 33.41M | 32.10M | 24.34M | — | 7.44M | 5.64M | 2.21M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.22M | $45.66M | $50.40M | $55.16M | $4.12M | $7.22M | $5.34M | $6.92M |
| Current assets | $43.18M | $48.24M | $52.73M | $56.46M | $5.53M | $8.64M | $6.12M | $7.37M |
| PP&E, net | — | — | — | — | — | $113,564 | $117,522 | $122,343 |
| Goodwill | — | — | — | — | $1.26M | $1.26M | $1.26M | $1.26M |
| Intangibles | $3.31M | $3.47M | $3.62M | $2.90M | $6.84M | $7.00M | $7.15M | $7.31M |
| Total assets | $46.49M | $51.71M | $56.35M | $60.24M | $13.63M | $17.01M | $14.66M | $16.06M |
| Current liabilities | $2.76M | $1.84M | $1.49M | $4.97M | $1.38M | $1.74M | $1.59M | $1.12M |
| Total liabilities | $2.76M | $1.87M | $1.54M | $5.02M | $1.42M | $1.83M | $1.68M | $1.28M |
| Shareholders' equity | $43.73M | $49.84M | $54.80M | $55.22M | $12.21M | $15.18M | $12.98M | $14.78M |
| Shares outstanding | 33.41M | 33.41M | 24.94M | 23.09M | 7.44M | 7.44M | 2.71M | 1.39M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.48M | -$4.71M | -$4.79M | -$5.40M | -$2.89M | -$3.87M | -$3.06M | -$2.44M |
| Financing cash flow | $0 | $8,476 | $750 | $56.42M | -$116,145 | $5.74M | $1.47M | -$23,550 |
| Depreciation & amortization | — | — | — | $421 | $24,000 | $4,000 | $4,821 | $4,717 |
| Stock-based compensation | $435,000 | $329,000 | $139,182 | $88,277 | $53,000 | $58,000 | $98,558 | $118,383 |
Free plan shows the latest 8 periods; Pro shows all 24 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.